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EDITORIAL REVIEW
The nature of clinical trials in nephrology
An editorial review may be defined as an assessment of a
topic presented from the point of view of the editor. A para-
phrase of this definition may be "an opinionated overview".
This latter broad definition seems appropriate in the present
review which presents this author's view on the manner in
which cooperative drug therapy trials might be organized in
relationship to nephritides. I will generally address glomerulop-
athies as an example for clinical trials, not only because this is
a major cause of renal morbidity and mortality, but because the
principles provided should apply to many other types of dis-
eases seen in nephrology such as hypertension, diabetes, inter-
stitial nephritis, etc. I further will focus mainly on the United
States, since this population is large and heterogeneous, the
data base is well developed for patients with end-stage renal
disease (ESRD), and the ideas espoused in many cases pertain
to studies performed in other Countries. The politics relative to
the U.S. are of course unique, but each country/region has its
own unique political environment with which to deal. As the
scope of this editorial is the general topic "Clinical Trials in
Nephrology", I will not deal with detailed analysis of any
specific trial or disease entities, many of which have been
individually addressed in other publications. The reader should
not interpret my use of the USA as a model to indicate that the
author perceives U.S. trials to be in any way superior to trials
in other countries. This simply provides a reasonable frame of
reference for delineating my suggestions.
The past
The history of clinical trials in nephrology spans many
centuries encompassing points in time prior to the definition of
nephrology as a distinct entity [1, 21. Anecdotal reports in-
cluded the effects of herbal remedies, leeches and blood letting,
and puncture of the lower extremities to release edematous
fluid. These beneficial therapeutic interventions were espoused
prior to any understanding of pathogenetic mechanisms of fluid
retention. Throughout the ensuing decades multiple approaches
to establish definitive therapies for various ailments affecting
the kidney have been reported. While good collaborative efforts
have been made in certain areas, notably pediatrics (Interna-
tional Study of Kidney Disease in Childhood, Southwest Pedi-
atric Nephrology Study Group) and in countries outside of the
USA (United Kingdom, Italy, France), the global applicability
of the results, especially to adults, remains to be proven. This
brings us to the present point in 1992 to define therapies of
proven benefit in various nephritides. It seems clear and ac-
cepted that steroids and cytotoxic therapies are indicated and
efficacious in both children and adults with minimal change
nephrotic syndrome. This then, represents a positive effect of
therapy. We also know that, contrary to great expectations,
plasma exchange is of little benefit in systemic lupus erythema-
tosus (SLE) glomerulonephritis [3]. However, despite literally
thousands of publications ranging from case reports to retro-
spective uncontrolled, case or cohort controlled studies, and
even randomized prospective trials, there is a surprising lack of
consensus regarding the most efficacious therapy for other
types of glomerulopathies.
The present
Of 300 million persons in the USA, kidney and urologic
diseases affect more than 13 million with an approximate cost of
$50 billion annually [4, 5]. More than 80 thousand deaths and 6
million hospitalizations per year are consequent to these dis-
eases. The direct cost to the federal government is almost $4.5
billion per year for patients on dialysis and receiving kidney
transplants. These funds provide support for more than 170
thousand patients. Other than hypertension, diabetes and gb-
merulonephritis are the leading causes of ESRD in the USA,
accounting between them for more than 50% of patients on
dialysis. Further, it is highly likely that this proportion will
increase as the incidence of ESRD secondary to diabetes now
approaches 40% in many centers. Thus, more than half of all
ESRD patients reach dialysis because of glomerulopathies.
Prospective clinical trials are currently under way to address
treatment for several of these entities [5, 6]. These include: the
large Modification of Diet in Renal Disease (MDRD) study
which addresses many types of chronic renal failure; the
Diabetes Control and Complications Trial, assessing the effect
of angiotensin converting enzyme (ACE) inhibitors in patients
with diabetes, which will provide information on diabetic
nephropathy; Angiotensin Converting Enzyme Inhibitor in Di-
abetic Nephropathy; and Prevention of Diabetic Nephropathy
in Insulin Dependent Diabetes Mellitus. These studies vary
greatly in the complexity of their design and the number of
patients anticipated to be enrolled, but focus on significant
issues in nephrology, that is, the most important causes of
progressive disease—diabetes and ESRD in general. While the
initiation, design, and accomplishment of these studies is highly
important and laudable, some of the confounding variables
noted below may influence the results and complicate interpre-
tation and recommendations that result therefrom, just as they
plague many previous studies.
Why do clinical trials?
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Perhaps the first question we as nephrologists should ask is,
why do we do clinical trials? The answer to that is somewhat
self evident—we wish to provide the best possible care for our
patients with minimal risk. While this may seem obvious, it is
not without controversy relative to the manner in which it can
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be accomplished. The nephrology literature is replete with case
reports, anecdotal data and strongly opinionated views about
efficacy of therapy. Yet we are woefully lacking in hard data to
support one position or another. Nonetheless, we individually
continue to advocate our favorite therapeutic views, attempting
to balance this lack of true scientific knowledge with the wish
and desire to provide our patients with the best, least risky care.
All espouse the concept of "primum non nocere", above all do
no harm, as a tenet of the Hippocratic Oath. Our intentions to
follow this mandate may be more successful than our actual
accomplishment thereof. The conflict between ethical issues of
individual physicians concerned with caring for their own
patients as a primary responsibility, versus participation in
clinical trials to derive an answer to a scientific question, has
been eloquently addressed [7, 8]. If, according to discussions by
Helman and Helman, we are bound by ethical dilemmas of
placing our patients in randomized prospective trials and must
obtain our information elsewhere, can we do this easily in
nephrology and what are the problems related to this? On the
other hand, if, as espoused by Passamni, it is entirely necessary
for "unproven treatments, that a properly performed random-
ized clinical trial (be done)", can we do this? Since it is this
author's opinion that the ultimate reason for doing clinical trials
is to obtain information for treating patients most efficaciously
with the least risk, then what kind of clinical trials could give us
this information?
Types of data sources for deriving information for patient
treatment
Decision analysis regarding therapy for patients can be
structured into a hierarchical pattern relative to the validity of
conclusions that can be drawn regarding therapeutic interven-
tion [9—12]. Clearly, personal observations in case reports
provide a disproportionately important emotional but scientifi-
cally vapid basis for selecting therapy. An improvement on this
anecdotal approach is the historical trials methodology. With
this technique patients treated in a particular fashion and their
clinical courses are compared retrospectively to a selected
group of patients with similar disease but receiving different
types of therapy. Historical controls have been the basis for
numerous publications in nephrology, influencing many of the
conclusions drawn to the present time regarding therapy. How-
ever, bias in patient selection in historical controls, improve-
ment in current modes of therapy, and changes in natural
course of disease almost invariably weigh the outcome of
studies utilizing historical controls in favor of new therapy. This
is recognized in nephrology as increasing attempts are made to
develop appropriately controlled, randomized prospective stud-
ies to examine intervention. Unfortunately, appropriately con-
ducted trials of this type are extremely expensive, complicated
to set up and run, and clearly may have limited application
except in certain areas.
Finally, a mathematical approach to obtain the same infor-
mation that can be derived from prospective randomized clini-
cal trials has been championed: meta-analysis [11, 121. Quanti-
tative meta-analysis provides a statistical mathematical
approach to pooling results from multiple trials. While this is an
attractive approach because it diminishes the need for large
full-scale prospective studies, there are a number of inherent
difficulties. Pooled results are significantly influenced by the
heterogeneous population of individual studies within the data
base and cannot take into consideration a variety of different
epidemiological or other factors that can be controlled in
prospective randomized trials. Furthermore, a significant Achil-
les heel for meta-analysis is the fact that trials examining
therapeutic options which have negative results are far less
likely to be published than trials that describe a positive effect.
Thus, it is likely that meta-analysis will always contain a bias
since its validity is dependent on containment within the
literature of the entire spectrum of negative and positive results.
Successful small clinical trials and meta-analysis are useful to
identify subsets of diseases responsive to therapy or to pinpoint
clinical endpoints which may permit more discrete clinical
trials. However, they direct the need for trials, rather than
diminish the need. Indeed, the literature is replete with such
trials that have not survived the rigors of appropriate large scale
studies.
Ethical considerations
The Hippocratic Oath expresses the primary duty of the
physician to the patient to treat the sick "according to my
ability and judgement" and to "keep them from harm and
injustice" from therapy [13]. In our zeal to provide the best for
our patients it can be quite difficult to determine what that best
may be. There may be a tendency to make light of side effects
or complications or to pay little credence to the quality of life of
the patient relative to our enthusiasm to cure the "disease".
These issues over the decades have been dealt with in far
greater detail and in weightier consideration than the present
editorial could ever approach. A recounting of the principles of
clinical trials as established by the Nuremberg code clearly
defines our responsibilities [13]. The principles are: (1) volun-
tary consent of the subject is essential; (2) the study should be
designed to yield results for the good of society that cannot be
obtained by any other method and should not be random or
unnecessary; (3) experiments should be based on the result of
animal experimentation and a natural history of the disease to
justify conduction of the study; (4) the experiment should be
conducted to avoid unnecessary physical or mental suffering or
injury; (5) no experiment should be conducted when there is
expectation that death or disability will occur; (6) the risk
should not exceed the humanitarian importance to be solved by
the experiment; (7) arrangement should be provided to protect
subjects against injury, disability, and death; (8) only scientifi-
cally qualified individuals should conduct the studies; (9) during
the experiment the subject should be at liberty to end the
experiment at his own desire; and (10) during the experiment
the scientist responsible for the study must be prepared to end
the experiment at any stage if continuation is likely to result in
injury, disability, or death to the subject(s). It has been argued
that the ethical dilemmas presented by clinical trials may well
put at variance the primary obligation of physicians caring for
patients, and has been recommended that "we must develop
and use alternative methods for acquiring clinical knowledge"
[7]. However, as a practicing clinical nephrologist who has
personally observed many individual patients undergo the rav-
ages of well thought out and well intentioned therapy, it is my
conviction that patients have an inalienable right to receive
therapy based on the best available scientific evidence. Therapy
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based on theory, rationale, and premise are not necessarily of
benefit, The only way to provide our patients with this infor-




In 1827 Richard Bright described an entity called glomerulo-
nephritis which in fact represented multiple renal diseases with
similar presentations [2]. Indeed, we know now that many of
those disease entities have quite different prognoses than oth-
ers. Knowledge of pathogenesis and disease course is important
in clinical trials, since the greater the degree in variability the
less able one is to extrapolate to the specific entity under
consideration. Our own experience in acute crescentic rapidly
progressive glomerulonephritis (AC-RPGN) has strongly ne-
gated the concept of lumping [14, 15]. The overall prognosis in
AC-RPGN was for many years considered abysmal with the
majority of patients proceeding to ESRD [14, 16]. However,
analysis of subtypes revealed that they could be clearly segre-
gated into an anti-glomerular basement membrane (anti-GBM)
group which had a very poor prognosis, and a variety of other
types which responded to pulse methylprednisolone or plasma
exchange [14—171. More recently a portion of the latter group
has been shown to have vasculitis related glomerulonephritis
and has been successfully treated by standard protocols, usu-
ally with addition of cyclophosphamide [18]. However, appro-
priately large controlled studies have not been done in AC-
RPGN, the long term risk benefit ratio is not clear, and
efficatious therapy for anti-GBM disease remains to be delin-
eated. In a similar manner, membranoproliferative glomerulo-
nephritis (MPGN) has clearly been shown to be divisible into
different categories which have quite different prognoses and
propensity to recurrence in grafts, with no clearly beneficial
methods of treatment [19—21]. Furthermore, the various his-
tologic subtypes of SLE nephritis are now well accepted as
carrying with them distinctly different prognoses [22]. Even
though all are considered subvariants of SLE nephropathy, in
terms of prognosis they might be considered as distinct clinico-
pathological entities. In addition, although the prognosis is
improved with present treatment, the optimal therapy for SLE
with acceptable associated complication rates remains to be
clearly defined [22, 23]. A similar scenario could be held for
focal glomerular sclerosis, IgA nephropathy, and membranous
glomerulopathy, where effective therapy with minimal thera-
peutic morbidity remain to be established [24—27].
Our few, well-controlled prospective randomized trials illus-
trate these principals. Thus, the plasma exchange in SLE study
focused on patients with a defined entity, that is, SLE, and
within the relatively narrow spectrum of severe renal disease;
the studies of ACE inhibitors in diabetic patients assume a
uniform population and pathogenesis; the MDRD study is based
on the "final common pathway" concept which presumes from
many elegant studies in animal models that hyperfiltration,
especially intraglomerular hypertension, is the pivotal factor in
progression of ESRD and that modification of this, as by diet,
will have beneficial effects [3, 22, 28, 29]. From this author's
perspective the latter may well be an oversimplification. Pre-
liminary reports from the MDRD study have shown highly
variable renal function among participants with very slow mean
rates of decline [30]. Nonetheless, regardless of the therapeutic
outcome, the MDRD study will provide important information
about the design and performance of similar studies in the
future. Only when appropriate information on the natural
course of diseases is available will we be able to make rationale
decisions for lumping and splitting. In the meantime, much
information albeit fragmented, is available. So what is worth
studying?
Consensus opinion
The decision regarding what disease entity to study and how
to conduct the study will be nearly as variant as there are
nephrologists interested in such studies. While there are many
mechanisms for addressing this issue, perhaps the most expe-
diant is to utilize the concept of "consensus opinion" [11, 31].
This methodology entails the assemblage of recognized leaders
in the field of nephrology to meet periodically to assess various
diseases and make recommendations of which studies should be
undertaken based on the best available data from previous
trials, pilot studies, personal observations, contact through
colleagues, the literature and other available methodology. The
recommendations should take into account the various factors
noted in the present editorial, the confounding variables of the
interrelationship between the National Institutes of Health
(NIH), Health Care Financing Administration (HCFA), and
industry. They should be promulagated upon the doctrine of the
cost benefit ratio, the expected complications and side effects of
the therapy, and the quality of life of the subjects with and
without therapy. The constituency of the panel should repre-
sent not only the well known highly visible academic leaders in
nephrology but also nephrologists known for their clinical
expertise and experience in patient care, and those experienced
in the conduction and participation in clinical trials.
Rational selection of therapies
Of pivotal importance in selecting therapeutic agents for
clinical trials is a sound rationale for therapy. The fortuitous use
of an agent of such high efficacy as to warrant appropriate trials
unnecessary is rare although cyclophosphamide in Wegner's
granulomatosis and prednisone in minimal change disease are
classic examples [24, 32]. In other situations the decision must
be based on clinical experience/judgement and data derived
from animal models. The latter is an appealing vehicle for
examining pharmacologic agents that may be of use in human
disease. Unfortunately, despite the plethora of experimental
models that delineate pathogenetic mechanisms, many of these
are not directly relevant to human disease [33]. Although most
forms of glomerulonephritis are presumed immunologic in
origin, the classic models used in the past have consisted of
administering antigen to result in formation of immune com-
plexes, or preformed immune complexes, or foreign anti-serum
raised against constituents of the kidney. None of these models
are directly applicable to the human setting since similar
pathogenetic mechanisms obviously do not pertain in human
disease [341. Only the autoimmune models seem pertinent to
human disease and there is surprisingly little information avail-
able about progression of these diseases of therapeutic modal-
ities that may be extrapolated to humans. Indeed, in the classic
studies of progressive glomerular sclerosis in animals, there is a
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distressing degree of variability in susceptibility to development
of the lesion and progression of disease [35]. The known high
propensity for various experimental models to require a given
species or even strain of animal for production of a morphologic
lesion similar to those observed in humans will continue to
perplex investigators attempting to utilize animal models of
human disease. These difficulties provide further impetus for
the development of animal models or in vitro human systems
that more accurately reflect pathogenetic mechanisms involved
in human disease [36].
The other approach to a rational selection of therapeutic
intervention relates to a more detailed knowledge of the natural
history of the disease and factors that influence progression.
Only by a careful chronicling of the natural disease course and
its variability can rational assessment be made, first of the need
for therapy, but secondly, the urgency of that need, and thirdly,
possible implications as to the type of therapy that might be
utilized. The confounding factors, noted below, provide an
even greater urgency for the need for epidemiologic time course
studies to define the natural course of disease.
Confounding factors
Histology
An understanding of the natural course of disease, its prog-
nosis, and the benefit of therapy presumes knowledge of the
underlying disease; for those who would use algorithms for
diagnosis, we in clinical practice and others have published the
fallibility of this approach [37, 38]. Not only is the histology in
non-diabetic disease imperative for diagnosis but for staging of
the disease and assessment of prognosis and response to
therapy. Correlates of this type are easiest to derive in a disease
with very rapid course, (such as AC-RPGN) but are also
present in other diseases as well. It is quite clear in essentially
all nephropathies that the degree of segmental sclerosis and
glomerular obsolescence as well as tubular atrophy and inter-
stitial fibrosis are of key importance in estimating the long term
outcome and response to therapy [15, 24, 39]. Not unexpect-
edly, there is also strong evidence that these parameters are
predictive of response to therapy as well. Furthermore, the
degree of histologic scarring present in biopsies, as might be
intuitively accepted, is related to the time course since the
initial insult. In addition to chronic changes in the interstitium,
an acute interstitial infiltrate may bode poorly for response to
therapy, and correlates with the degree of renal impairment
[40—42]. A simple diagnosis of a type of glomerulopathy is
insufficient for classification of disease for clinical trial pur-
poses. Much more additional information must be provided
regarding the morphology of the kidney.
Hyperlipidemia
Much evidence suggests that hyperlipidemia in animals is
pivotally important in the progression of glomerular sclerosis,
and that therapeutic agents directed to lowering lipid levels are
of benefit in animal models. The possible mechanisms by which
elevated lipids may be involved in progressive glomerular
sclerosis in renal damage have been reviewed and provide
compelling indirect evidence in patients with hyperlipidemia,
that this may be a confounding factor in the progression of the
underlying renal disease [43]. It is likely, just as cardiovascular
disease is accelerated in this setting in patients with renal
disease, that future epidemiologic studies will show a negative
effect of hyperlipidemia on glomerular lesions in humans.
Pat ho genetic factors
It is becoming increasingly clear that many of the glomerular
diseases that nephrologists see clinically are influenced by the
genetic constitution of the patient [44—49]. This is true not only
in diabetes but in many immunologic diseases. These genetic
associations are likely more than simply associations, and it is
possible that certain genetic markers carry with them an in-
creased risk not only of the underlying disease but of worse
prognosis for the underlying renal disease. Examples of this are
IgA nephropathy in Western versus Oriental patients, a worse
clinical course of diabetes in Pima Indians, and the known
influence of sex on prognosis in membranous nephropathy
[50—52]. While many of these genetic associations are related to
the major histocompatibility complex (MHC), as would be
expected in view of the key role of the interaction of the MHC
and the T-cell receptor in autoimmune phenomena, it is likely
that other non-MHC loci play important roles in ancillary
systems of import, that is, endogenous steroids, sex hormones,
the prostaglandins, the renin-angiotensin, and other hormonal
systems involved in renal function and dysfunction [53, 54].
Proteinuria
For many years the presence and degree of proteinuria has
been a marker of renal dysfunction and rate of progression
regardless of whether the underlying glomerulopathy was in-
flammatory or non-inflammatory [55]. It is not clear whether
proteinuria is a factor which causes progression of renal disease
or is a marker of the progression of the underlying histologic
lesion; nonetheless, proteinuria clearly segregates patients into
prognostic categories relative to the degree of proteinuria. The
quantity of proteinuria correlates both with glomerular and
tubulointerstitial processes in animals and in humans. While the
mechanisms of the poorer clinical course of disease associated
with proteinuria are not known, Cameron has postulated that
worsened hyperlipidemia as well as a hypercoagulable state and
release of various platelet associated growth factors may be
involved in the worse prognosis associated with heavy protein-
uria [55].
Hypertension
There is nearly universal acceptance of the fact that hyper-
tension has a negative influence on any type of renal disease,
and that control of hypertension is perhaps our most important
therapeutic intervention in most patients with renal dysfunc-
tion. While it is not yet clear whether control of hypertension
with ACE inhibitors of calcium channel blockers provides any
advantage over conventional control, it is clear that the rate of
progression of renal disease is related to the presence or
absence of hypertension and the degree of blood pressure
elevation [56].
Compliance
A key factor in prolonged clinical trials of the type necessary
in nephrology is the ability of patients to maintain the therapeu-
tic regimen [57, 58]. It behooves the investigator to design as
simple a regimen and follow-up as is feasible for the goals of the
Bolton: Clinical trials in nephrology 1065
study since lack of compliance can lead to an unacceptably high
dropout rate and inconclusive results. Furthermore, individuals
enrolled in the study are more likely to be compliant with a
given regimen than patients in a non-study setting. The results
of the complicated MDRD study in terms of compliance will be
important in addressing this issue.
Ethnic-socio-economic factors
Therapeutic trials may utilize pharmacologic agents, dietary
manipulations or other maneuvers which, when supported by
the funding agency, are feasible as therapeutic alternatives for
the patient group in question. Studies should be designed with
an eye to future utilization of regimens in non-study patients.
As those of us who see patients clinically realize, no matter how
good a therapeutic option is available to the patient, if the
patient is unable or unwilling to purchase and utilize the
regimen, it will be useless. Furthermore, the social constraints,
that is, dietary habits of certain ethnic groups, may render the
ability to utilize dietary manipulation extremely difficult or
impossible in the environment of the social group perse [58].
Unless these factors are considered in the design of trials and
controlled, apparent differences in outcome may relate more to
food preferences/habits than to the intervention in question!
End point/parameter of response
One of the most problematic difficulties in the design of a
clinical trial and the long term course of patients has to do with
the selection of the end point to determine if the intervention is
effective. The vagaries of the use of creatinine clearance as an
estimate of glomerular filtration rate (GFR) and the utility of
isotopic GFR determinations have been discussed previously
and will not be addressed here [59]. It is clear from experience
to the present, however, that because of the natural tendency
for study design to include patients who have progressive
decreases in kidney function, these patients cannot serve as
their own controls for a number of reasons, including impor-
tantly regression to the mean (meaning that the extreme vari-
ability that selected them into the study will correct during the
study). Furthermore, it appears likely that a prolonged period of
follow-up will be necessary to truly ascertain significant
changes in renal function either pro or con, suggesting that four
to five years or more may well be necessary to include most
patients under study [30, 56, 59, 60]. Confounding factors in
GFR that occur during that period of time need to be considered
relative to the assay system in use. For instance, a change in
body habitus, muscle mass, creatinine generation, dietary hab-
its, the assay system for serum creatinine all may influence
creatinine clearance [56, 59]. Although some centers find the
endogenous serum creatinine to be an acceptable and reliable,
reproducible, methodology to follow GFR [61], it is the bias of
the present author from both personal experience and from the
literature, that the "gold standard" should be isotopically
determined GFRs. The end point will then need to be selected
in each study but with consideration to the variability in renal
function inherent to the study group under examination, and
should represent a continuum. Furthermore, the selection of
the end point should consider a number of variables other than
simply the need for dialysis or transplantation. The social
situation for the patient and the quality of life are more
important variables than the mathematical assignment to ESRD
or transplantation.
Effect of provider support
Conduction of clinical trials, per force by their very nature,
requires an increased level of interaction between the subjects
and the medical care team than is routine in most clinical
settings. This "placebo" or "clinic" effect has been variously
attributed to phenomena noted above, that is, regression to the
mean of serum creatinines, and to the intense level of medical
care team input relative to diet, medications, blood pressure
control, and closer adherence of subjects to the regimen [62—
64]. There is also evidence that the presence of sufficient
concern and support for a patient can have an independent
overall beneficial effect and positively influence patient out-
come. For example, dialysis patients who were the subject of
increased provider support demonstrated a statistically better
compliance and medical management than a control group that
received standard intervention [65]. The beneficial effect was
related to continuation of the provider support and was lost
with discontinuance of provider support. Thus, chronically ill
patients, for whom compliance is a significant element for
morbidity prevention, are an especially susceptible group to the
provider effect. This appears to be directly applicable to long-
term studies necessary in renal diseases. While numerous
studies have alluded to the beneficial effect in placebo groups
related to increased provider support, this has not been appro-
priately addressed as a safe and effective therapeutic modality
in and of itself. Intuitively, tautologically and from consider-
ations of multiple published studies, this would seem to be an
extremely important confounding factor in all clinical trials.
Sample size
The number of subjects necessary to achieve statistically
significant and clinically important differences in clinical trials
may not necessarily be the same, but both are related to the
underlying natural course of the disease and effectiveness of the
therapeutic intervention. The worse the natural prognosis of the
process, the fewer the numbers of subjects will be required to
demonstrate a significant beneficial effect of therapeutic inter-
vention; conversely, the more variable the underlying natural
course, the greater will be the number of subjects required to
achieve statistical significance. As the number of confounding
factors noted above and uncertainty regarding the clinical
course for a given disease entity increases, so also does the
demand for increased numbers of patients to provide the power
necessary to detect differences between groups. While stratifi-
cation for variables can compensate to some degree for these
problems, the stratification process itself requires additional
numbers of individuals to reach significance. Thus, ideally, our
patients would have a homogeneous constitution relative to the
confounding variables described above, a known and predict-
able time course of their disease process, and would conse-
quently afford us the potential for a statistically meaningful
result with a reasonable number of subjects. Unfortunately, this
is an ideal seldom realized in nephrology. For any clinical trial,
the input from an independent statistical center will be neces-
sary to determine sample size, preferably using data derived
from epidemiologic data basis.
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Academia
The proper conduct of clinical trials requires much more than
simply a protocol. The integrated participation of all concerned,
including particularly the physicians, is essential. The investi-
gators need to be involved from the conceptualization of the
study, through its design, development and implementation.
The major focus of academic nephrology here and abroad for
many decades has related to bench research with major empha-
sis on physiologic processes. Funding for research, publication
of manuscripts, academic advancement, and indeed the success
of many academic careers depends upon the successful accom-
plishment of basic research. The result has been the implication
that clinical studies are less important, less intellectually chal-
lenging, and of significantly less importance for academic
advancement. Clinical trials seldom bring fame to investigators,
require a great deal of time, work, and effort, and are extremely
demanding. By their very nature they require a multi-center
approach to develop the necessary basis for the study, thereby
requiring cooperation between centers—no mean feat in itself.
Inherent to trials are the physiologic variations alluded to above
making the rigorous application of scientific stringency which
can be achieved at the bench extremely difficult. These factors
have always negatively influenced the ability of investigator-
initiated clinical trials to receive appropriate funding, made the
funding of fellowships for clinical research very difficult, and
have resulted in the perception, probably correct, that building
an academic career based on clinical research as a mode of
advancement is extremely risky. These problems parallel cur-
rent controversies on how to evaluate and reward the teacher
who is responsible for training physicians of the future. The
multiple inherent difficulties associated with the design and
development of a clinical trial greatly heightens the liklihood of
priority scores not resulting in funding. Consequently, in
nephrology the number of investigator-initiated clinical trials is
abysmally low, mechanisms for providing high quality training
for individuals to conduct clinical trials is vanishingly sparce,
and we in academic nephrology find ourselves to be neophytes
in the design and conduction of clinical trials. Academic
nephrology must address and resolve these career issues to
allow a new type of academic nephrologist to emerge with the
likelihood that venturing into the appropriate training for the
conduction of clinical trials will result in career achievement,
recognition, and stature comparable to colleagues conducting
"pure" science.
Money
The cost of conducting clinical trials is truly staggering
relative to the return for funds in the basic science areas. This
is especially true for the chronically progressive diseases in
nephrology and because of factors in populations noted above.
In these days of diminishing research funding, the spectre of a
large expensive clinical trial syphoning funds originally avail-
able for basic research induces many emotions in the research
community, perhaps best summarized as negativism! In view of
the huge cost of these trials, collaboration with dollars from
research, (NIH) patient care (HCFA) and private industry
which stands to benefit from successful therapeutic interven-
tion, represents a model approach to financing.Nonetheless, the
difficult interaction in balancing scientific structure of studies
with the financial outlay involved in the somewhat different
objectives of industry nearly demands the wisdom of Solomon
in negotiations for conduct of trials of this nature. It seems clear
that compartmentalization of funds, not infringing upon basic
research dollars, is mandatory for conduction of clinical trials.
This in turn brings into play complex issues of the interaction
between the U.S. Congress and the nephrologic community.
While this issue will not be addressed further, suffice it to say
that the involvement of Congress with allocation of specific
targeted funds for specific clinical trials is essential if proper
trials are to be done in nephrology.
The people
Over the past several decades the mystique surrounding the
medical profession and scientific world has been largely dis-
pelled. No longer are physicians held in deified aloofness, but as
a professional component of society not unlike others. The
scientific community has been considerably shaken over the
last decade by fraud or the perception of fraud by the public, by
the arrogant misuse of funds, and the internecine conflicts of
some of our most prominent scientists. The people, in the form
of the Congress of the United States, are no longer content to
supply funds for biomedical research for the sake of knowledge
per se. Hard decisions will need to be made in the future
regarding the direction of basic research with funding of those
projects which seem most relevant to real human pathology,
morbidity and mortality with much tighter scrutiny of those
endeavors in which direct relevance to pathologic processes are
less obvious. It seems clear to this author that basic science
studies of all types will need to heed this directive and that more
funds will be targeted to basic and clinical research in which the
benefit to the public is clearly obvious.
Recommendations
In 1987 the National Kidney and Urological Diseases Advis-
ory Board established by Congress began developing a long
range plan which was to be the first national ten year plan to
combat kidney and urologic diseases [61. This gargantuan effort
involving the suggestions and advice from many professional
and lay individuals as well as patients from every walk of life
involved in kidney and urologic diseases was published in
March 1990, and represents a stellar distillation of the problems
facing the nephrologic and urologic community on a broad
based front. The result of this plan, the National Kidney and
Urologic Advisory Board, 1990 Long Range Plan: Window on
the 21st Century, provides recommendations relative to all
spheres of kidney and urologic diseases. The author enthusias-
tically endorses those recommendations which are summarized
in Table 1. The recommendations in this editorial are directed
more towards the issues noted above, specifically related to
cooperative drug therapy in various nephrititis and does not
presume to reflect the extensive in-depth, detailed recommen-
dations by the Advisory Board, although there will clearly be
some significant overlap for the purpose of emphasis.
National registry
Because of the factors noted above, it is imperative that a
broad base of information be obtained on the various disease
entities to better guide the development of clinical trials. The
United States Renal Data System (USRDS) is an exemplary
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Table 1. Summary of goals and recommendations by the National
Kidney and Urologic Diseases Advisory Board [6]
(1) Improve understanding of the scope and impact of kidney and
urologic diseases through expanded data collection and analysis.
(2) Promote fundamental and applied research efforts that will serve
as the basis for new preventive, diagnostic, and therapeutic
strategies.(3) Improve the quality of and access to medical care appropriate to
the diversity of kidney and urologic diseases and the populations
they strike.
(4) Improve public, patient, and professional awareness of the
opportunities for prevention, early detection, treatment, and
rehabilitation.
(5) Expand research training and funding and improve application of
research findings to kidney and urologic disease patients through
technology transfer and education.
(6) Provide an organizational focus for kidney and urologic diseases.
(7) Insure equitable access to quality care of kidney patients.
(8) Provide optimal human resources for patient care.
model which is facilitated by its nature, but could logically be
used as the cornerstone of a national epidemiologic registry for
various types of renal disease seen by nephrologists in all types
of practice. Extant data bases should also be incorporated
("piggy backed") when possible.
Cost benefit ratio
While some trials could be accomplished in a single or only
several centers, the majority of meaningful trials will require
multi-center collaborative efforts. In view of the great cost of
these it is clearly important to utilize an analysis of the cost
benefit ratio to pick those diseases deserving of large scale
clinical trials. Selection would be related to epidemiologic
studies of various diseases as well as data in the USRDS.
Selection of trials
A panel of experts encompassing NIH, HCFA, the pharma-
ceutical industry, and nephrologists and urologists should be
established to make recommendations for areas of clinical trials
to be targeted. While some of these areas may be selected based
on current knowledge and information about the course of
disease, others will require data derived from the registry.
Trial design
Trials should be randomized, prospective, and controlled in
nature. Placebo or "standard" therapy groups should, of
course, be used as simultaneous controls run concurrently with
the test groups. The selection of controls will depend on the
entity under study. Trials should take into consideration the
confounding factors briefly described herein. The protocols
should provide sufficiently long follow-up to establish an irre-
futable result and should include an assessment of beneficial
effect, quality of life and complications of therapy.
Selection of trial therapy
Selection of trial therapy should be based on information
from experimental models and available data including meta-
analysis and other types of trials. Consensus opinion should be
utilized for selection of the trial therapy and should be based on
the best pathophysiologic information available.
Safety efficacy
Each clinical trial should have an independent epidemiologic
component which actively participates in the trial, an indepen-
dent biostatistics division which independently participates in
the design and conduct of the trial, and an independent safety
monitoring board for constantly accessing the safety of the
therapeutic modality. These branches should function indepen-
dently of the trial and yet be actively interactive with the trial.
Stop points should be set to provide the greatest possible
opportunity to detect experimental differences without undue
patient morbidity and mortality. The specific selection of stop
points will depend upon the treatment modality and disease
entity being studied.
Population base
Great efforts should be made to include representative indi-
viduals of all races, sexes, and ages, and to represent a cross
section of the population base. Centers for studies should be
based not just in large cities but should provide representation
of urban and rural segments of the country and be geographi-
cally distributed to represent the whole spectrum of the geo-
graphic United States. Special emphasis to include appropriate
ethnic groups should be provided and stratification based on
epidemiologic characteristics of the given disease should be
included prospectively.
Investigator-initiated clinical studies
These should not be discouraged but should be fostered and
considered in the light of factors described in the present
editorial. Appropriately designed investigator-initiated trials
could serve as pilot studies preparatory to large scale multi-
center clinical trials or as a basis for targeted funded clinical
studies. They should receive standard peer review scrutiny. In
addition, clinical trials established through consensus opinion
should ultimately undergo independent peer review of design
and overall methodology.
Cooperative ventures
The various public and institutional organizations involved in
active lobbying of Congress should mount a combined effort in
cooperation with industry and NIH to obtain support for
clinical trials outside of the normal channels for investigator-
initiated research and with appropriate length of time and
degree of funding for these projects. Only through concerted,
cooperative, and organized efforts as a united group can these
goals be accomplished efficiently. Divisiveness and a lack of
concerted effort will result in low Congressional enthusiasm and
lack of appropriate funding for needed clinical studies.
The clinical investigator
Continued efforts must be made so that future clinical inves-
tigators can be appropriately and well trained, can function as
equals in academic nephrology/urology and will not be per-
ceived as second class citizens in their own academic institu-
tions relative to promotion, tenure, and academic advance-
ment. This major hurdle is an absolutely necessary one for the
future of clinical trials in nephrology and is the responsibility of
the scientific community in toto. This must include not only the
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appropriate recognition of the value of the clinical investigator
but appropriate financial support as well.
The Kidney/Urology Institute
It is essential that as part of the emergence of nephrology and
urology as a distinct group, that an independent institute be
established at NIH and that this Institute of Kidney and
Urologic Diseases have as one of its mandates the development
of a more balanced perspective of basic research relative to
pathophysiologic processes and to clinical trials.
The public
The public provides the support for our research—the re-
search must provide an adventageous cost:benefit clearly ap-
plicable to human renal disease. If we do not orient our research
directives with these goals uppermost in consideration, then the
people and their Congress will do it for us. We must educate
and inform the public of work ongoing and needed, and empha-
size public relations so that we approach Congress with the
support of the people.
In summary, the issue of clinical trials in nephrology is a
complex one. The specialty of nephrology is relatively new and
we have only recently begun to venture into the area of
appropriate clinical trials. It is obvious that there are many
issues that need to be addressed as we move toward the
selection and conduct of trials in areas of importance to the
patients we see as nephrologists. It is already apparent that the
leadership in nephrology at the level of academic nephrology,
the NIH, industry, and HFCA are venturing cautiously but
appropriately into the cooperative arena for the design of
studies that will be necessary in the coming decades. Much
work remains to be done to lay the foundation for the conduc-
tion of these trials and to obtain the major support needed from
our patients by way of Congress. It is critical that the recom-
mendations of the National Kidney and Urological Diseases
Advisory Board be implemented and that we prepare to con-
duct clinical trials of drug therapy in nephrology. While the
present paper focuses on the USA, many principles apply to
other countries, although each country's specific problems will
relate to ethnic, cultural, political, and socio-economic factors
unique to that region. The overzealous attempt to expedite
trials without the proper foundation of epidemiologic and patho-
physiologic basis, and expert investigators, may compromise
the information to be received, necessitate revision of trials and
repetition, and result in expensive trials and complications for
subjects. This author, however, is convinced that the compli-
cations and long-term side effects of drugs which we use with
good conscience for our patients may yet lie undiscovered for
lack of careful extended follow-up with these specific questions
in mind. Hopefully, within the next two decades we nephrolo-
gists will be able to point with pride to our own studies which
conclusively prove beyond the scrutiny of all, that a given
therapy is beneficial and has an acceptable complication rate.
However, we will not reach this point until the appropriate
foundations are laid, and correctly designed and conducted
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